ObjectiveTo investigate the efficacy of laser photocoagulation and intravitreal ranibizumab treatment of retinopathy of premature(ROP). MethodsThis study included 49 ROP infants (96 eyes), including type 1 pre-threshold ROP (7 infants, 14 eyes), threshold ROP (38 infants, 44 eyes) and aggressive posterior ROP (AP-ROP, 4 infants, 8 eyes). According to the treatments received, all patients were divided into laser photocoagulation (LP) group (40 infants, 78 eyes) and intravitreal ranibizumab (IVR) treatment group (9 infants, 18 eyes). Generally, zoneⅡand stage 3 ROP with clear refractive media received laser photocoagulation, zoneⅠROP and AP-ROP, or eyes with unclear refractive media or infants with poor general condition received IVR. The infant gestational age, birth weight, corrected gestational age at first treatment and the cure rate of the first treatment were analyzed between the two groups, and between three disease types (type 1 pre-threshold, threshold and AP-ROP). ResultsThe gestational age and birth weight was no difference between the LP group and IVR group (t=0.827, 1.911; P > 0.05). The corrected gestational age at first treatment of LP group was significantly smaller than that in the IVR group (t=3.041, P < 0.05). In the LP group, 75 of 78 eyes (96.15%) was cured by the first treatment, 3 of 78 eyes (3.85%) progressed to stage 4A after the first treatment and was controlled by vitrectomy. In the IVR group, 8 of 18 eyes (44.44%) was cured by the first treatment, 10 of 18 eyes (55.56%) progressed to next stage after the first treatment and was controlled by additional laser photocoagulation or repeated IVR. The gestational age and birth weight was no difference between type 1 pre-threshold, threshold and AP-ROP infants (t=2.071, 0.664; P > 0.05). The corrected gestational age at first treatment of type 1 pre-threshold infants was the same of the threshold lesion infants (t=2.054, P > 0.05). The corrected gestational age at first treatment of AP-ROP infants was significantly smaller than that of type 1 pre-threshold and threshold lesion infants (t=3.250, P < 0.05). The cure rate was statistically significant (χ2=24.787, P < 0.05) between there three ROP lesions. ConclusionIVR treatment is suitable for zoneⅠlesions, AP-ROP and Plus lesions, while laser photocoagulation is appropriate for zoneⅡlesions with fibrosis and less vascular proliferation.
Objective To explore the effect of oxygen inhalation on the retinae of newborn rats and its mechanism.Methods We mimicked the retinopathy of prematurity(ROP) by putting the newborn rats in high concentrated oxygen. One-day old rats were put into the oxygen box with the oxygen concentration of 80% for continuous 7 days; then in air condition for 7 days. The arterial blood oxygen pressure, retinal superoxide dismutase (SOD), and malondialdehyde (MDA) of the rats (1,2,4,7,8,9,11,14 days old) were examined. The diameter of retinal vessels′main branch and the coverage rate of peripheral vessels were measured in 7- and 14-day-old rats by ink perfusion. The retinal neovascularization of rats (8,9,11, 14 days old) were observed by HE staining. The rats of the same age fed in air condition were in the control group.Results The differential pressures of blood oxygen of rats (1,2,4,7 days old) in study group were significantly higher than those in the control group (P＜0.01), while the differential pressures of blood oxygen of rats (8,9,11,14 days old) in study group were lower than those in the control group (P＞0.05). The contents of SOD of the retinae in the rats ( 1,2,4,7,8 days old) were significantly lower than those in the control group(P＜0.01, P＜0.05 ), while the contents of MDA were significantly higher than those in the control group (P＜0.01,P＜0.05). The diameter of retinal vessels′main branch in 7-day rats was 75% of the control group, and the coverage rate of peripheral vessels was 22% of the control group; and was 61% and 73% respectively in 14-day-old rats. The neovascularization could be seen in 16.7% of the rats in the study group and nought in the control group.Conclusion The damage of free radical of the retina in high concentrated oxygen and hypoxia situation after oxygen supply may be one of the most important mechanism of ROP. (Chin J Ocul Fundus Dis，2003，19：269-332)
Retinopathy of prematurity (ROP) is one of the leading causes of visual impairment in children. As understanding on the pathogenesis of ROP accumulated, anti-vascular endothelial growth factor (VEGF) drugs and their application have changed the treatment mode. Anti-VEGF therapy, with convenient operation and clear efficacy, has become an important treatment method for ROP. However, due to the dysfunction of organs in children with ROP, anti-VEGF drugs can enter blood circulation after intravitreal injection and then lead to temporarily reduction of the VEGF level in the blood, which may theoretically cause adverse effects on the development of all organs (especially the brain) in children with ROP. Therefore, it's necessary to pay attention to the effect of anti-VEGF drugs on neurodevelopment in children with ROP, strictly grasp the indications, and standardize its clinical application, so as to continuously improve the overall prognosis of ROP.
ObjectiveTo analyze the risk factors of severe retinopathy of prematurity (ROP) and provide consultable evidence for the rational establishment of screening standard.MethodsThe clinical data of 168 prematureinfants (gestational age less than 37 weeks) who was diagnosed in our department from Dec 2002 to Apr 2004 was analyzed retrospectively. Gender, birth count (BC), gestational age (GA), birth weight (BW), duration of oxygen therapy and vascularization devlopment of posterior and peripheral retina examined by binocular indirect ophthalmoscope after mydriasis were recorded. The results were recorded by the international classification of ROP (ICROP), and stage 1, 2 and 3 were mild ROP while threshold disease, stage 4 and 5 were severe ROP. Logistic regression was appliedto analyze the relationship of ROP and gender, BC, GA, BW, and oxygen therapy. ResultsSevere ROP was found in 91 eyes (27.1%) of 47 infants (28.0%) in 336 eyes of 168 premature infants, including threshold disease in 20 eyes (6.0%) and disease at stage 4 in 11 eyes (3.3%) in which the diseases at stage 4A was foundin 2 eyes (0.6%) and stage 4B in 9 eyes (2.7%). There were 60 eyes (17.8%) at stage 5. In all of the factors, GA, BW and oxygen therapy were found to have a significant impact on severe ROP (P=0.000, 0.000 and 0.015,α=0.05) while gender and BC were not (P=0.640 and 0.084, α=0.05). Statistic analysis of subgroupshowed that the risk of severe ROP in premature infants would increase significantly when GA≤30 weeks, BW≤1500 g or oxygen therapy gt;4 days. Conclusions Severe ROP relates to GA, BW and oxygen therapy instead of gender and BC. The risk of occurrence of severe ROP in premature infants increases significantly when GA≤30 weeks, BW≤1500g or oxygen therapy gt;4 days, so it is recommended to screen such premature infants carefully. (Chin J Ocul Fundus Dis,2005,21:271-274)
Retinopathy of prematurity (ROP) is a retinal angioproliferative disease that occurs in premature and low birth weight infants, and is the most common eye disease that causes blindness and low vision in infants. However, there is no systematic standardized guidance on the overall treatment strategy for ROP. Therefore, in order to standardize the treatment of ROP, the Ophthalmology Group of Pediatrics Society of Chinese Medical Association organized relevant domestic experts to put forward standardized opinions on the treatment of ROP in China after repeated discussion, so as to provide clinicians with reference and application in clinical practice.
Objective To determine the association between the geneti c polymorp hisms of vascular endothelial growth factor (VEGF) gene and the prognosis for retinopathy of prematurity (ROP) in Chinese. Methods Twenty infants with threshold ROP who had undergone retinal photocoagulation were in the treated group and 20 infants with self-regressed ROP without any treatment were in the control grou p . In the two groups, all the infants had oxygen-breathing history and the sex a n d gestational age were all suitable to be compared, except birth weight. Polymer ase chains reaction-restriction fragment length polymorphism was used to determine the frequencies of VEGF genes in the two groups. Results The frequencies of +405C allele were higher in the treated group than those in the control group (P＜0.05). The frequencies of the VEGF-460T/C and +936C/T ploymorphisms were similar in both groups (P＞0.05). Conclusions The +4 05C/G ge netic polymorphisms of VEGF may correlate to the prognosis of ROP. The carriers of +405CC allele are more susceptible to ROP.
ObjectiveTo analyze the regulative rule of mRNA of vascular endothelial growth factor (VEGF) in mice with oxygen-induced retinopathy, and to elucidate the possible mechanism of occurrence of neovascularization in retinopathy of prematurity (ROP).MethodsSixty 7-day-old C57BL/6J mice were divided into oxygen-induced retinopathy group and control group. In oxygen-induced retinopathy group, 36 mice were exposed to 75% oxygen for 5 days and then to room air for 5 days; in control group, 24 mice were raised in room air. Vascular perfusion of fluorescein and retinal stretched preparation were used to observe the morphologic changes of retinal vessels. Reversal transcriptionpolymerase chain reaction (RT-PCR) was used to observe changes of VEGF mRNA in each group. ResultsIn oxygen-induced retinopathy group, the morphologic characteristics of retinal vessels were the unperfused area at the center of superficial and deepseated vessels, and the neovascularization appeared at mid-peripheral retina after 2 days in relative hypoxia condition. The results of RT-PCR showed space-time corresponding relation between expression of VEGF and neovascularization, which meant that the transcription of VEGF mRNA decreased in hyperxia conditionand increased in relative hypoxia condition. ConclusionHypoxia is the main reason of occurrence of retinal neovascularization; increased expression of VEGF caused by relative hypoxia after hyperxia might be effective in reducing the occurrence of neovascularization in ROP.(Chin J Ocul Fundus Dis, 2005,21:292-295)
ObjectiveTo observe the effect of intravitreal injection of conbercept in the treatment of retinopathy of premature (ROP) and to analyze the factors related to the therapy.MethodsA retrospective study. A total of 57 patients (57 eyes) with pre-threshold type 1 (30 patients, 30 eyes), threshold ROP (21 patients, 21 eyes) and acute aggressive posterior ROP (APROP, 6 patients, 6 eyes)) from premature infants by retinal screening in Henan Provincial People’s Hospital during October 2017 and June 2018 were enrolled in this study. All children were received routinely intravitreal injected 10 mg/ml conbercept 0.025 ml (0.25 mg) within 24 hours after diagnosis. Fundus examination was performed 7 days after injection. The interval of examination was 1?3 weeks according to fundus conditions. The mean follow-up was 30.1±4.6 weeks. For patients with relapse or no response to treatment, repeated intravitreal injection of conbercept or laser photocoagulation therapy was given. The retinal blood vessels of the affected eyes were observed. Logistic stepwise regression analysis was used for the correlation test of multiple factors.ResultsAmong 57 eyes, 49 eyes and 8 eyes were treated with 1 or 2 times of intravitreal injection of conbercept. After 24 weeks of treatment, in 57 eyes, 26 eyes were cured (45.6%), 22 eyes improved (38.6%), 8 eyes relapsed (14.0%), and 1 eye aggravated (1.8%). The recurrence time was 12.9±4.5 weeks after the first injection, and the corrected gestational age was 49.0±6.7 weeks. There were significant differences in initial injection time, lesion range among the cure, improved and recurrence eyes (F=5.124, 7.122; P＜0.01, ＜0.01). Parameters of ROP condition, including ROP diagnosis (pre-threshold type 1, threshold and APROP), zone (zone 1 and 2), stage (stage 2 and 3) and plus lesions, were significant different among the cure, improved and recurrence eyes (χ2=11.784, 14.100, 6.896, 9.935; P＜0.01, ＜0.01, ＜0.05, ＜0.01). Logistic stepwise regression analysis showed that the recurrence rate was correlated with ROP zone, more likely recurrence at zone 1 than zone 2 (Wald=9.879, OR=27.333, P=0.002). No injection-related complications such as endophthalmitis, cataract and glaucoma were found during treatment and follow-up period.ConclusionsIntravitreal injection of conbercept is effective in the treatment of ROP without obvious adverse reactions. Lesion zoning is associated with recurrence after treatment.
ObjectiveTo investigate the relationship between peripheral blood inflammatory markers and the development of retinopathy of prematurity (ROP) in extremely low birth weight infants (ELBWI), and to preliminarily evaluate their predictive value for ROP. MethodsA retrospective clinical study. A total of 191 ELBWI who were born at The Affiliated Hospital of Qingdao University and admitted to the neonatal intensive care unit between January 2018 and December 2023 were enrolled. According to the presence or absence of inflammation-related diseases (necrotizing enterocolitis, bronchopulmonary dysplasia, neonatal sepsis), infants were divided into an inflammation-related disease group (144 cases) and a non-inflammation-related disease group (47 cases). Clinical data and peripheral blood inflammatory markers at 7, 14, and 28 days after birth, including white blood cell count (WBC), C-reactive protein (CRP) level, neutrophil-to-lymphocyte ratio (NLR), and systemic immune-inflammation index (SII) that were compared between the two groups, as well as between infants with and without ROP within the inflammation-related disease group. Logistic regression analysis was used to identify variables associated with the occurrence of ROP. A receiver operating characteristic (ROC) curve was constructed to assess the predictive performance of the combined model, and decision curve analysis (DCA) was applied to evaluate its potential clinical utility. ResultsAmong the 191 infants included, 80 cases were diagnosed with ROP (41.9%, 80/191). The incidence of ROP was 68/144 (47.22%) in the inflammation-related disease group and 12/47 (25.53%) in the non-inflammation-related disease group, with a statistically significant difference between the two groups (χ2=6.849, P=0.010). In the inflammation-related disease group, compared with infants without ROP, those with ROP had lower birth weight (Z=?2.591) and gestational age (Z=?2.942), a lower proportion of cesarean delivery (χ2=5.846), longer durations of invasive and noninvasive mechanical ventilation (Z=?2.500, ?2.057), and a higher incidence of patent ductus arteriosus (χ2=4.598) (P＜0.05). Levels of inflammatory markers were significantly higher in the ROP group, including WBC and SII at 7 days (Z=?2.85, ?2.565), SII at 14 days (Z=?2.531), and WBC, NLR, and SII at 28 days after birth (Z=?2.385, ?3.051, ?2.719; P＜0.05). In contrast, CRP levels at 7, 14, and 28 days did not differ significantly between ROP and non-ROP infants (Z=?1.550, ?0.796, ?0.132; P＞0.05). Multivariate logistic regression analysis showed that decreased birth weight [95% confidence interval (CI) 0.990-0.998] and increased WBC at 7 days (95%CI 1.004-1.129) and SII at 28 days (95%CI 1.001-1.006) after birth were independent related factors for the occurrence of ROP (P＜0.05). ROC curve analysis indicated that the area under the curve for predicting ROP by combining birth weight, WBC at 7 days after birth, and SII at 28 days was 0.71, with a sensitivity of 91% and a specificity of 44%. DCA shows that when the risk threshold is 31% to 98%, this combined prediction model has a positive net clinical benefit. In the non-inflammation-related disease group, only birth weight was negatively correlated with the occurrence of ROP (95%CI 0.975-0.996, P=0.005). ConclusionsIn ELBWI patients with inflammation-related diseases, the levels of peripheral blood WBC and SII are associated with the occurrence of ROP. The combination of birth weight and inflammatory indicators at specific time points has certain predictive value for ROP.
Objective To observe the inhibitory effect of Bevacizumab on retinal neovascularization in oxygen-induced retinopathy in the mouse. Methods 90 one-week-old C57B L/6J mice were divided into four groups at random. 15 mice in the 1st group as normal control group, 15 mice in the 2nd group as oxygen control group, 30 mice in the 3rd group as high-dose Bevacizumab treatment group, 30 mice in the 4th group as low-dose Bevacizumab treatment group. The 2nd, 3rd and 4th groups were exposed to 75% oxygen for 5 days and then to room air. At the 12th day, One eye of each mouse of two control groups were received an intravitreal injection with Be vacizumab at 2 mu;l、1 mu;l respectively, and the same volume of BSS was injected into the other eye of the mice. The adenosine diphosphatase (ADPase) histochemical technique was used for retinal flat mount to assess the oxygen-induced change s of retinal vessels. The number of the endothelium cell nuclei of proliferative neovascularization was quantified by retinal microtome chromoscopy. Real-time PCR analysis was performed to examine the expression of VEGF mRNA. Results Comparing with oxygen control group, regular distributions, reduced density of retina l vascular and reduced endothelium cell nuclei which extending retinal membrane were observed in the treatment groups(P＜0.001). But the differences between two treatment groups are not statistically significant (P＞0.05). The expression of VEGF mRNA was not significantly different in oxygen control group whatever it whether accepted Bevacizumab treatment or high or low dose (P＞0.05). Conclusion Intravitreal injection with Bevacizumab can effectively inhibits the retinal neova scularization in oxygen-induced retinopathy in the mouse. Intravitreal injection with Bevacizumab might become to the new method to treat retinopathy of premature. （Chin J Ocul Fundus Dis，2008，24：184-188）